Journal of the American Academy of Dermatology
-
J. Am. Acad. Dermatol. · May 2001
Randomized Controlled Trial Multicenter Study Clinical TrialImiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial.
Superficial basal cell carcinoma (sBCC) is an increasingly common tumor in fair-skinned populations throughout the world. Imiquimod, an immune response modifier that induces cytokines including interferons, has been shown in preliminary studies to have an effect when applied topically to BCC. ⋯ Imiquimod 5% cream appears to have potential as a patient-administered treatment option in sBCC.